John Lally1, Jennifer Brook2, Thomas Dixon2, Fiona Gaughran3, Sukhi Shergill3, Narbeh Melikian4, James H MacCabe3. 1. Department of Psychosis Studies, King's College London and National Psychosis Service, South London and Maudsley NHS Foundation Trust, London SE5 8AF, UK. 2. National Psychosis Services, South London and Maudsley NHS Foundation Trust, London, UK. 3. National Psychosis Services, South London and Maudsley NHS Foundation Trust, and Department of Psychosis Studies, Institute of Psychiatry, Kings College London, London, UK. 4. Cardiology Unit, King's College Hospital, London, UK.
Abstract
OBJECTIVES: Clozapine is the most efficacious treatment for treatment-resistant schizophrenia; however its use can be limited by intolerability. Sinus tachycardia is a common adverse event associated with clozapine use, which may lead to the premature discontinuation of clozapine. Traditionally, β blockers are used to treat clozapine-associated tachycardia, though problems with intolerability and ineffectiveness can limit their utility. METHODS: In this article, we present two cases of patients with treatment-resistant schizophrenia who developed symptomatic tachycardia associated with clozapine therapy. RESULTS: We demonstrate that the novel heart rate controlling agent ivabradine can be effectively and safely used to control the heart rate and to allow for continued treatment with clozapine. CONCLUSION: This is the first report in the literature demonstrating that ivabradine appears to be a well tolerated agent, which should be considered as a symptomatic treatment of clozapine-induced tachycardia if the use of a β blocker fails due to a lack of response or intolerability.
OBJECTIVES: Clozapine is the most efficacious treatment for treatment-resistant schizophrenia; however its use can be limited by intolerability. Sinus tachycardia is a common adverse event associated with clozapine use, which may lead to the premature discontinuation of clozapine. Traditionally, β blockers are used to treat clozapine-associated tachycardia, though problems with intolerability and ineffectiveness can limit their utility. METHODS: In this article, we present two cases of patients with treatment-resistant schizophrenia who developed symptomatic tachycardia associated with clozapine therapy. RESULTS: We demonstrate that the novel heart rate controlling agent ivabradine can be effectively and safely used to control the heart rate and to allow for continued treatment with clozapine. CONCLUSION: This is the first report in the literature demonstrating that ivabradine appears to be a well tolerated agent, which should be considered as a symptomatic treatment of clozapine-induced tachycardia if the use of a β blocker fails due to a lack of response or intolerability.
Authors: Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi Journal: Lancet Date: 2010-09-11 Impact factor: 79.321
Authors: Dennis T Ko; Patricia R Hebert; Christopher S Coffey; Artyom Sedrakyan; Jeptha P Curtis; Harlan M Krumholz Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Björn M Nilsson; Oscar Edström; Leif Lindström; Petter Wernegren; Robert Bodén Journal: Int Clin Psychopharmacol Date: 2017-07 Impact factor: 1.659